Rizzo A, Breda A, Moretto F, Pace M, Dotta C, Gelso E, Sanzuol F, Tossani C
Divisione Medica, USL 12, Ospedale di Valdobbiadene (TV).
Clin Ter. 1993 Mar;142(3):243-50.
Sixty patients, recognized as chronic alcoholics on the grounds of the case history and with a score above 11 of the Munich Alcoholism Test (MALT) have been treated with metadoxine or placebo for thirty days according to a double blind randomized design. In the group treated with active drug there has been a significant reduction higher than in the controls of the scores relating to the abstinence symptomatology, in particular regarding the neuropsychic residual symptomatology (anxiety, depression, insomnia) after the first week of treatment, a reduced requirement of benzodiazepines and/or neuroleptics, and a significant decrement higher than in the controls of the score of MALT at the end of treatment. Furthermore, metadoxine seems to make easy the maintenance of abstinence, at least at short term.
60例根据病史被认定为慢性酒精中毒且慕尼黑酒精中毒测试（MALT）得分高于11分的患者，按照双盲随机设计，接受了30天的美他多辛或安慰剂治疗。在接受活性药物治疗的组中，与戒酒症状相关的得分，特别是在治疗第一周后与神经精神残留症状（焦虑、抑郁、失眠）相关的得分，比对照组有显著降低，苯二氮䓬类药物和/或抗精神病药物的需求量减少，且在治疗结束时MALT得分比对照组有显著下降。此外，美他多辛似乎至少在短期内便于维持戒酒状态。
